🧬 This Week in Vaccine Research: Shingles, Liver Cancer, Universal Flu & COVID-19 Updates & More
This week’s Vaccine Research roundup features breakthrough updates—from a shingles vaccine showing enhanced immune responses, to game-changing cancer immunotherapies and progress on a universal flu vaccine. Stay informed on the key innovations transforming vaccine science and global health.
🔬 Key highlights:
🦠 Dynavax’s Z-1018 shingles vaccine delivers 100% antibody response and nearly 90% stronger CD4⁺ T-cell activation compared to Shingrix
🧠 PDS Biotech reports nearly 40-month survival in head and neck cancer with PDS0101 and Keytruda combo
❌ FDA suspends Valneva’s Ixchiq chikungunya vaccine after 4 serious adverse events, including 1 fatal encephalitis case
🧬 Liver cancer patients gain 8 extra months of progression-free survival with a first-of-its-kind dendritic cell vaccine
💰 Osivax secures $19.5M in funding to advance OVX836, a universal flu vaccine targeting the stable nucleoprotein
💉 Pfizer-BioNTech’s COMIRNATY updated COVID-19 vaccine approved in the U.S. for high-risk groups ahead of Fall 2025 rollout
🧒 GC Biopharma launches Phase 3 trial for chickenpox vaccine Barycela in Thailand to rival Merck’s Varivax
📢 Stay Ahead in Vaccine Research!
✅ Like, share, and subscribe for weekly updates on the latest vaccine breakthroughs
#VaccineResearch #CancerVaccines #FluVaccine #COVID19Vaccines #ShinglesVaccine #DendriticCellTherapy #Chikungunya #VaccineInnovation #ClinicalTrials #GlobalHealth #LucidQuest #InfectiousDiseases #BiotechNews #PharmaceuticalUpdates #SubscribeNow